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Autoreactive CD41 T Cells Protect
from Autoimmune Diabetes via Bystander
Suppression Using the IL-4/Stat6 Pathway
ªoral toleranceº and refers to prevention and treatment
of autoimmune diseases by oral administration of anti-
gens related to autoimmune target tissue-specific anti-
gens. While high-dose regimens were shown to result
in deletion or ªanergyº of autoreactive lymphocytes spe-
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variety of animal models for autoimmune disease, in-²Novo Nordisk A/S
cluding type 1 diabetes, the generation of such regula-Krogshojvej 53a
tory cells by oral immunization (oral tolerance) has beenBagsvaerd
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arthritis (Tada et al., 1996), diabetes (Bergerot et al.,
1994), and tolerance to ovalbumin (Garside et al., 1995a,
1995b) or bovine alpha s1-casein in splenocyte-recon-Summary
stituted SCID mice (Yoshida et al., 1998). Recently,
TCRgd T cells (reviewed in Kapp and Ke, 1997) haveTargeted immune regulation can be achieved by use
been demonstrated to mediate oral tolerance in experi-of tissue-specific T cells and offers the potential for
mental autoimmune uveitis (EAU) (Wildner and Thurau,organ-specific suppression of destructive autoim-
1995) and to ovalbumin (McMenamin et al., 1994, 1995;mune processes. Here, we report the generation and
Mengel et al., 1995; Ke et al., 1997). CD8/TCRgd T cellscharacterization of insulin B chain±specific ªautoreac-
capable of diabetes prevention in NOD mice have alsotiveº CD41 regulatory T cells that locally suppress dia-
been reported after aerosol insulin (Harrison et al., 1996).betogenic T cell responses against an unrelated self-
However, not much is known about their precise anti-antigen (viral transgene) in a virus-induced model for
genic specificities and effector mechanism(s).type 1 diabetes. Interleukin 4 (IL-4) is essential for
The special immune environment for lymphocyteprevention of diabetes since regulatory T cells cannot
priming at large mucosal surfaces may be critical in thebe induced in the absence of IL-4 or stat6 (IL-4 signal-
generation of regulatory cells, which are characterizeding pathway). Our observations demonstrate that au-
by their ability to secrete cytokines such as interleukintoreactive regulatory T cells can suppress autoreac-
4 (IL-4), IL-10, and TGFb and can act as suppressivetive destructive T cell activity of differential antigenic
regulatory cells if they are able to home to an autoim-specificity locally in the pancreatic draining lymph
mune targeted site and prevent disease. This mecha-node, probably via cytokine-mediated modulation of
nism has been termed ªbystander suppressionº if theantigen-presenting cells.
specificity of regulatory cells differs from that of the
autoreactive destructive lymphocytes. Bystander sup-
Introduction pressor cells have been suggested in EAE (Miller et al.,
1991, 1993; al-Sabbagh et al., 1994; Chen et al., 1994)
Autoreactive lymphocytes are usually thought of as de- and arthritis (Zhang et al., 1990; Yoshino et al., 1995),
structive mediators of autoimmune disease. However, and their existence was strongly suggested in our virus-
autoreactive lymphocytes capable of amelioration or induced diabetes model (von Herrath et al., 1996; von
prevention of autoimmune disease were also described Herrath and Homann, 1997). In some cases, phenotypic
and termed regulatory cells. In type 1 diabetes, a T analyses were performed to characterize bystander
cell±mediated autoimmune disease characterized by suppressor cells (Miller et al., 1991), and other studies
the specific destruction of insulin-producing b cells in documented production of TGFb (Miller et al., 1993),
the pancreatic islets of Langerhans, splenic b cell± IL-4, and IL-10 (von Herrath et al., 1996; Weiner, 1997).
reactive CD41 T cells as well as thymic regulatory cells To our knowledge, only one study has demonstrated
were shown to prevent diabetes after adoptive transfer phenotypic and functional analysis of bystander sup-
into prediabetic nonobese diabetic (NOD) mice (Sempe pressor T cells induced by oral antigen administration:
et al., 1994; Akhtar et al., 1995; Herbelin et al., 1998). A EAE was prevented by CD41 regulatory cells that se-
promising strategy to therapeutically induce and expand creted TGFb, IL-4, IL-10, and IFNg (Chen et al., 1994).
such regulatory cells in vivo has been collectively called However, these regulatory clones were structurally iden-
tical to Th1-type encephalitogenic CD41 clones in T cell
receptor usage, MHC restriction, and epitope recogni-§ To whom correspondence should be addressed (e-mail: matthias@
scripps.edu). tion. This and further observations in a transgenic T cell
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Table 1. Adoptive Transfer of Insulin-Specific, IL-4-Producing Regulatory Cells Protects Prediabetic RIP-NP Recipients
Cytokines Produced
by Transferred Cells
Amount and Source Cells Stimulated Diabetes
of Transferred Cells in Presence of IFNg IL4 Incidence
No transfer N/A N/A N/A 100%
2±2.5 3 105 CD41 T cells B chain/IL-4 0.12 0.10 0%
(PDLN, protected donor) B chaina 0.12 0.00 100%
5 3 106 splenocytes B chain 0.33 0.90 50%
(protected donor) LCMV-NP118-126 3.21 0.16 100%
5 3 106 splenocytes B chain 1.40 0.11 83%
(diabetic donor) LCMV-NP118-126 2.80 0.13 100%
Regulatory cell lines derived from pancreas draining lymph node (PDLN) of RIP-NP mice receiving oral insulin treatment were expanded in
the presence of porcine insulin B chain, IL-2, and IL-4. After 2 months, IL-4 was withdrawn and cells subsequently tested in vitro (cytokine
profiles) and in vivo (adoptive transfers). In some experiments, IL-4 was withdrawn for more than 2 months, resulting in a cytokine profile
switch as indicated. Additional lines were derived from spleens of orally treated mice and propagated on porcine B chain or the MHC class
I±restricted LCMV-NP118-126 peptide (RPQASGVYM) as a control. Recipient RIP-NP mice were infected with LCMV i.p. and 5 days post infection
received 2 to 2.5 3 105 PDLN-derived regulatory cells i.v. or 5 3 106 cultured splenocytes i.p. Blood glucose levels were monitored weekly,
and diabetic mice were euthanized after two consecutive blood glucose measurements of .300 mg/dl. IL-4 but not IFNg production by PDLN-
derived regulatory cells correlated with protection. Differential stimulation of spleen cell lines also showed that increased IL-4 production was
associated with protection. Increase of IFNg secretion by stimulation with LCMV-NP118-126 completely abrogated protective capacity of trans-
ferred spleen regulatory cells. Cytokine production is expressed in ng/100 ml tissue culture supernatant after stimulation cultures of cell
numbers as indicated for transfers. All ELISAs were performed three times, and SE was ,15%. a.2 months IL-4 withdrawal.
receptor (TCR) system (Chen et al., 1996) argued that profile similar to that reported for other regulatory cells,
namely production of IL-4, IL-10, and some IFNg (Weinerantigen-specific autoreactive T cells can differentiate in
vivo into autoaggressive or regulatory cells depending et al., 1994; von Herrath et al., 1996; Weiner, 1997). When
transferred i.v. into prediabetic RIP-NP mice, regulatoryon the site and context of the initial priming event. How-
ever, no model has so far clearly demonstrated by- cells proliferated only in the pancreatic draining node of
recipients and completely protected from autoimmunestander suppression by using two distinct, defined self-
antigens. diabetes by locally suppressing the virus (self)-specific,
ªdiabetogenicº T cell responses. IL-4 and the signalTo address the potential mechanism of bystander
suppression in type 1 diabetes, we took advantage of transducer and activator of transcription 6 (stat6), a criti-
cal component of the IL-4 signaling pathway (Kaplan etthe well-defined primary self (LCMV)-antigen in the RIP-
LCMV transgenic system of virus-induced autoimmune al., 1996), were essential for induction of regulatory cells
as demonstrated by the failure to efficiently protect RIP-diabetes (von Herrath et al., 1996). The transgenic RIP-
NP line used in this report expresses the nucleoprotein NP 3 IL-42/2 or RIP-NP 3 stat62/2 mice from diabetes
by oral insulin treatment. Our results show that diabetes(NP) of lymphocytic choriomeningitis virus (LCMV) under
the control of the rat insulin promoter (RIP) in b cells of prevention likely occurred through IL-4/stat6-mediated
modulation of antigen-presenting cells (APCs) resultingthe pancreatic islets of Langerhans (Oldstone et al.,
1991; von Herrath et al., 1994a, 1994b). Only after infec- in decreased expansion and cytokine secretion of auto-
reactive CD81 and CD41 T cells. These findings providetion with LCMV, progressive destruction of b cells that
express the viral NP eventually leads to overt type 1 direct evidence for bystander suppression in a dual self-
antigen-specific model.diabetes following approximately 1 week after viral
clearance. Development of disease is dependent on NP-
specific CD81 T cells, CD41 T help, as well as IFNg (von Results
Herrath and Oldstone, 1997). We have shown previously
that oral insulin can prevent diabetes in these mice (von Insulin B Chain±Specific Regulatory T Cells Are
Generated by Oral Insulin Immunization andHerrath et al., 1996). Protection is associated with a
ªmixedº ªTH1/TH2º type cytokine profile in the pancreas Prevent Diabetes after Adoptive Transfer
into Prediabetic Recipientsand a local (pancreas) but not systemic abrogation of
NP-specific (ªanti-selfº) CTL activity. While these results Based on our previous studies using oral administra-
tions of porcine insulin to prevent diabetes in RIP-NPstrongly suggested bystander suppression as the mech-
anism for oral tolerance induction, a specific regulatory mice (von Herrath et al., 1996; Homann et al., 1999), we
hypothesized that this procedure generated regulatoryT cell population had not been directly demonstrated,
and it is not precisely understood how and where TH2 T cells with likely specificity for the immunodominant
insulin B chain. Given the different T cell phenotypescytokines could suppress autoreactive CTL.
In this report, we derived cell lines from pancreatic among regulatory cells, crude lymphocyte cultures were
established from pancreas draining lymph nodes (PDLN)draining lymph nodes of RIP-NP mice protected from
type 1 diabetes by porcine insulin feedings. Lympho- of protected or diabetic mice treated with oral insulin
as well as nonfed mice. Cultures were maintained in thecytes were cultured in the presence of the immunodomi-
nant insulin B chain (Daniel and Wegmann, 1996; Polan- presence of insulin B chain and IL-2, as well as IL-4.
Only cultures from protected mice survived long enoughski et al., 1997; Homann et al., 1999) or B chain peptides.
Analysis of established cell lines revealed a cytokine to allow for sufficient expansion to test the cell lines in
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Figure 1. Pancreatic Immunohistochemistry of Diabetic and Protected Mice/Trafficking of Regulatory T Cells
(A and C) CD4 and CD8 lymphocytes found in islets of nonprotected diabetic RIP-NP mice. The histology shown is representative for mice
receiving CD41 ªregulatoryº cell transfers from diabetic donors or no cell transfers. Pancreata were harvested on day 21 post LCMV.
(B and D) CD4 and CD8 lymphocytes found in islets of protected nondiabetic RIP-NP mice that received regulatory cell transfers (day 5 post
LCMV); pancreata were harvested on day 21 post LCMV.
(E and F) Pancreatic draining node (PDLN [E]) or pancreas (F) from RIP-NP transgenic mouse receiving transfer of BrdU-labeled lymphocytes
from a RIP-NP donor treated with oral insulin and protected from diabetes. Splenocytes from oral insulin±protected or unprotected mice were
cultivated for 3 days in the presence of IL-4 insulin B chain and labeled overnight with BrdU (prior to transfer). Cells (5 3 106) were transferred
into prediabetic (day 5 post LCMV) RIP-NP recipients. Organs were harvested 36 hr later and stained for BrdU. Significant amounts of labeled
cells were only found in the PDLN (E), very few cells in the spleen (data not shown), and none in the pancreas (F). The experiment was
performed three times.
vitro and in vivo. Phenotypic analysis of these cell lines immunodominant LCMV NP118-126 peptide abrogated the
protective capacity of such cells (Table 1). The minimaldemonstrated a homogenous population of TCRab
bearing CD4hi T cells. No expression of CD8 or TCRgd protection (17%) observed after adoptive transfer of in-
sulin B chain stimulated splenocytes from oral insulin±was detected (data not shown).
Adoptive transfers of 2 to 2.5 3 105 regulatory CD41 T treated yet diabetic mice suggested that oral insulin led
to the generation of regulatory cells, however presum-cells into prediabetic RIP-NP mice (5 days after infection
with LCMV) led to complete protection from type 1 dia- ably at frequencies too low to prevent diabetes in such
donors.betes (Table 1). Interestingly, long-term withdrawal of
IL-4 from cultures, while neither affecting regulatory cell
proliferation in the presence of insulin B chain nor their CD41 Regulatory T Cells Produce IL-4, IL-10, and IFNg
Cytokine profiles of regulatory T cell cultures were deter-surface phenotype, abolished this protective effect (Ta-
ble 1). Histologically, diabetes prevention was associ- mined by ELISA and flow cytometry. As shown in Figure
2A, protective regulatory CD41 T cells produced IL-4,ated with a mild perinsulitis consisting mainly of CD41
T cells. In contrast, nonprotected mice showed pro- IL-10, as well as IFNg in response to stimulation with
insulin B chain. The loss of protective function followingnounced CD81 T cell infiltration and destruction of islets
(Figures 1A and 1C versus 1B and 1D). IL-4 withdrawal from cultures was accompanied by a
switch in cytokine profile: retention of IFNg productionIn control experiments, splenocytes from insulin-fed
protected and unprotected RIP-NP mice were also but dramatically reduced IL-4 and IL-10 secretion (Fig-
ure 2A; Table 1). Similar results were obtained after poly-stimulated in the presence of insulin B chain (and in
some instances IL-4) or, alternatively, in the presence clonal stimulation of protective and nonprotective CD41
T cell lines and enumeration of cytokine-producing cellsof the immunodominant, MHC class I±restricted LCMV-
NP118-126 peptide. Only splenocyte cultures from pro- by intracellular cytokine staining (Figure 2B). In addition,
TNFa, which is largely membrane bound and not detect-tected mice stimulated in the presence of B chain were
able to efficiently protect prediabetic RIP-NP recipients, able under the ELISA conditions employed, was found
in approximately 2.5-fold more nonprotective than pro-although to a lower degree (50%) than the PDLN-derived
cell lines. In contrast, stimulation in the presence of the tective CD41 T cells by intracellular cytokine staining
Immunity
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Figure 2. Cytokine Profiles of CD41 Regula-
tory T Cells
Regulatory T cells were recovered from the
pancreas draining lymph node of RIP-NP
mice treated with oral procine insulin and cul-
tured under conditions detailed in the Experi-
mental Procedures. Cultured cells were ex-
clusively CD41, CD82, TCRab1, and TCRgd2.
Protective but not nonprotective regulatory
cells produced IL-4 and IL-10. (A) Regulatory
cell cultures were stimulated for 3 days with
procine B chain, and cytokines secreted into
supernatant were analyzed by ELISA. After
polyclonal stimulation with plate-bound anti-
CD3, nonprotective regulatory cells demon-
strated z800-fold increased IFNg production (37.7 6 9.3 ng/50 ml) as well as some IL-4 (10.0 6 2.5 pg/50 ml) and IL-10 (7.7 6 4.2 pg/50 ml)
production (data not shown). (B) To determine cytokine profiles by flow cytometry, cells were stimulated for 5 hr with PMA/ionomycin in the
presence of Brefeldin A prior to surface and intracellular staining.
(Figure 2B). No IL-2 could be detected by either method. a more pronounced increase of IL-4 than IL-10 produc-
tion in the pancreas (von Herrath et al., 1996). BasedA comparable shift in cytokine production was also ob-
served in splenocyte cultures differentially stimulated on these findings, we therefore hypothesized that IL-4
might be the key regulatory cytokine for suppression ofwith insulin B chain or the LCMV-NP118-126 peptide (Table
1). Such pronounced differences in cytokine production diabetes onset and tested this notion using oral insulin
immunization in IL-4-deficient mice that were crossedwere not observed in splenocyte cultures derived from
insulin-fed but diabetic mice. These data demonstrate to the RIP-NP background. As shown in Figures 3A and
3B, protection could be readily induced in transgenicthat oral insulin immunization can generate specific
CD41 T regulatory cells that can be isolated and ex- mice heterozygous for IL-4 but did not occur in IL-4-
deficient RIP-NP mice treated with porcine insulin. Fur-panded in vitro and completely protect prediabetic RIP-
NP recipients from type 1 diabetes after adoptive trans- ther studies were initiated in order to understand
whether the highly specific stat6-dependent IL-4 signal-fer, if they are secreting IL-4 and IL-10 (Figure 2).
ing pathway (Kaplan et al., 1996) was required for effec-
tive generation of regulatory T cells in RIP-NP mice.Regulatory T Cells Are Not Generated in the Absence
Insulin feeding did not prevent diabetes in stat6-defi-of IL-4 or Stat6
cient RIP-NP mice, whereas it protected in stat6-compe-Earlier studies using RIP-NP mice that overexpressed
tent littermates (Figures 3C and 3D). Interestingly, a geneIL-4 or IL-10 in the pancreatic islets have shown that
dose effect of the stat6 gene appears possible, sinceIL-4 had a clear protective effect whereas IL-10 slightly
protection occurred to a somewhat lesser extent in oralenhanced diabetes following LCMV infection (Lee et al.,
insulin±fed stat6 heterozygous mice (Figure 3D). Ab-1994; R. Muller, personal communication). Furthermore,
insulin-immunized, protected RIP-NP mice demonstrated sence of IL-4 or stat6 did not affect the kinetics of virus
Figure 3. RIP-NP Mice Develop Type 1 Dia-
betes in the Absence of IL-4 or Stat6 but Are
Refractory to Induction of Regulatory T Cells
by Oral Insulin Immunization
Mice were bred and genotyped as detailed in
the Experimental Procedures. Diabetes was
defined as two consecutive blood glucose
measurements of .300 mg/dl. (A and B) Inci-
dence of diabetes in untreated (vehicle) and
oral porcine insulin±treated (0.5 mg twice per
week) RIP-NP mice that were IL-41/1, IL-41/2,
or IL-42/2. There were no significant differ-
ences between IL-41/1 and IL-41/2 groups;
thus, only the data for IL-41/2 mice are dis-
played. (C and D) Incidence of diabetes in
untreated and oral insulin±treated RIP-NP
mice that were stat61/1, stat61/2, or stat62/2.
Mice were followed up to 6 months post in-
fection, and no further cases of diabetes were
observed over this timespan. The size of the
experimental groups is noted in parentheses.
Significant (p , 0.05, log-rank test) differ-
ences were found between oral insulin±
treated IL-41/- and IL-42/2 mice and between
oral insulin±treated stat61/1 and stat62/2 mice.
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clearance (data not shown) nor the generation of LCMV-
specific cytotoxic T lymphocytes (CTL) since compara-
ble systemic CTL activity was detected in all mice tested
(Figure 4A). However, in contrast to diabetic mice, RIP-
NP mice protected by oral insulin treatment did not have
detectable virus-specific, i.e., autoreactive destructive,
T cells in the pancreas. These results demonstrate the
presence of local immune regulation without apparent
effect on the systemic immune response.
The Pancreas Draining Lymph Node Is a Critical
Compartment for Regulatory T Cell Function
C. Kurts and his colleagues (Kurts et al., 1997, 1998,
1999) had identified the PDLN as an essential check-
point in the development of autoimmune diabetes. To
analyze the distribution and localized activity of trans-
ferred regulatory T cells in our prediabetic RIP-NP recipi-
ents, tracking experiments with bromodeoxyuridine
(BrdU)- and CFSE-labeled regulatory cells were per-
formed. Spleen, lymph nodes (axillary, mesenteric, in-
guinal, and PDLN), and pancreas were harvested 2, 4,
24, 36, and 48 hr after transfer and analyzed for the
presence of labeled cells. While transferred cells were
readily detected in all lymphatic organs, (data not
shown), no cells labeled by either method could be de-
tected in the pancreas (Figure 1F). However, when ana-
lyzed for proliferation, transferred CD41 T cells only di-
vided in the PDLN but not other lymphoid organs, as
early as 4 hr post transfer into prediabetic RIP-NP mice
(Figure 4C), and were detectable there at significant
numbers for a prolonged period of time (36 hr, Figure
1E, and up to 3 days, data not shown). In accordance
with the selective local proliferation of regulatory cells,
suppression of LCMV-specific T cell responses was
found only in the PDLN in vivo (Figure 4B, intracellular
cytokine staining), demonstrating that the PDLN is the
essential compartment for negative regulation of de-
structive, diabetogenic T cell responses by autoreactive
regulatory lymphocytes.
IL-4 Differentially Modulates the Function
of Stat6-Competent and -Deficient APCs
While the local suppression of LCMV-specific T cell re-
sponses in the PDLN results from regulatory T cell acti-
vation by cross-presented insulin B chain, it remains
unclear how insulin B chain±specific CD4 T cells can
in different lymphocyte compartments. Protected mice exhibit a
Figure 4. Local Suppression of Virus-Specific CD81 T Cell Re- selective suppression of NP-specific CD8 T cells in the PDLN.
sponse in Pancreas and PDLN-Selective Proliferation of CD41 Regu- (C) CD41 regulatory T cell cultures were established from spleens of
latory T Cells in PDLN protected and diabetic mice and labeled with CFSE prior to adoptive
transfer into prediabetic RIP-NP recipients as detailed in the Experi-(A) Splenic and pancreas infiltrating lymphocytes were prepared 45
mental Procedures. A left shift in fluorescence intensity indicatesdays after LCMV infection of IL-4 or stat6-deficient RIP-NP mice
proliferation of labeled cells. Panels are gated on CFSE1 CD41 Tand their IL-4 or stat6 wild-type littermates. Protection was achieved
cells. CD4 regulatory cells from protected donors proliferate selec-by oral insulin administration. Lymphocytes were restimulated and
tively in the PDLN of recipients 4 hr post transfer (upper panel). Noassayed for CTL activity as detailed in the Experimental Procedures.
proliferation was observed in other lymphatic organs or after transferNo significant differences in CTL activity were observed in spleens
of similarly treated cells from diabetic donors (lower panel). Furtherof IL-4 or stat6-competent or -deficient mice. However, protected
proliferation was observed at later time points post transfer (data notmice exhibited markedly reduced CTL activity in the pancreas. ND,
shown), indicating that regulatory cells (although reaching multiplenot determined.
lymphoid organs) selectively proliferated in the PDLN, and only there(B) After adoptive transfer of splenic CD41 regulatory T cells, pro-
were they found in detectable numbers at later time points (comparetected and diabetic RIP-NP mice were analyzed by flow cytometry
Figure 1E, BrdU labeling).for presence of LCMV-NP-specific, IFNg-producing CD81 T cells
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Table 2. IL-4 Suppresses Virus-Specific T Cell Effector Function via Modulation of APCs
CD41 T Cells CD81 T Cells
Cytokines Added LCMV-Specific Cytotoxicity
APC Genotype Effector T Cell Genotype to Culture (% 51Cr Release) % of Total % IFNg1 % of Total % IFNg1
stat61/1 stat61/1 none 10 15 6 65 23
IL-4 0 36 2 10 15
IL-12 38 20 23 68 64
stat62/2 stat62/2 none 15 10 11 50 51
IL-4 60 14 10 59 71
IL-12 20 20 16 40 43
stat61/1 stat62/2 none 13 18 7 70 28
IL-4 0 20 5 8 12
Splenocytes were harvested from LCMV-infected stat6-deficient or -competent mice and cultured in the presence of IL-4 (8 ng/ml), IL-12 (4
ng/ml), or no cytokines. APCs were LCMV-infected/uninfected or NP118-126-pulsed/nonpulsed, irradiated (2000 rads) stat6-deficient or -competent
PECs. 2 3 105 APC/well were added to all cultures kept in 24-well plates. After 6 days, supernatants were harvested for ELISAs, and cells
were harvested for CTL assays and FACS analysis. Staining for intracellular IFNg was preceded by a 5 hr restimulation with anti-CD3 and
anti-CD28. In some experiments, IL-4 (4 ng/ml) was directly added to the chromium release assay. No suppression of CTL activity was
observed; however, there was a slight tendency toward increased bulk CTL activity (10%±15% above regular killing). Results were obtained
in two (FACS) to four (CTL assay) independent experiments; SE was , 6 15% for all values shown.
lead to suppression of CD8 T cells specific for an unre- Discussion
lated antigen (LCMV-NP). We hypothesized that rather
In the present report, we document that autoreactive,than, or in addition to, acting directly on T cell effectors,
regulatory T cells specific for one self-antigen (insulinregulatory T cells might induce a modulation/ªdeactiva-
B chain) can locally decrease activity of destructive au-tionº of APCs that subsequently fail to promote or ac-
toreactive lymphocytes specific for a different self-anti-tively suppress T cell activation to other presented anti-
gen (LCMV-NP) in a model of type 1 diabetes and there-gens. To test this hypothesis, we analyzed the effect of
fore act as ªtrueº bystander suppressors. The effect isIL-4 and IL-12 (control) on expansion and activation of
highly dependent on the ability of these regulatory CD41LCMV-specific T cell effectors restimulated by LCMV-
T cells to produce IL-4, which decreases the activity ofinfected APCs or APCs pulsed with the immunodomi-
autoreactive destructive T cells depending on the stat6nant LCMV NP118-126 peptide (Table 2). APCs were perito-
pathway in APCs, since it neither occurs after IL-4 depri-neal exudate cells (PEC) expressing uniformly CD11b
vation of isolated B chain±specific regulatory cells norwhile only a small fraction also coexpressed CD11c. In
in the absence of stat6-competent APCs (see also Figureaccordance with our in vivo findings (Figure 4B), addition
3). Thus, autoreactive regulatory cells can be a potentof IL-4 but not IL-12 to restimulation cultures reduced
tool to treat IDDM, even if the primary eliciting self-expansion and LCMV-specific cytolytic activity as well
antigen is not precisely known.as the numbers of IFNg producing CD81 and CD41 virus-
In contrast to oral antigen treatment, which protectedspecific effector T cells. While IL-4 induced slight
50%±60% of treated mice (von Herrath et al., 1996; Ho-changes in expression of costimulatory molecules (such
mann et al., 1999), adoptive transfer of in vitro expandedas 25% CD40 upregulation on PECs), no other pro-
B chain±specific regulatory cells resulted in completenounced differences were observed. In contrast, when
protection. This high degree of protection after transferthe same experiment was performed with stat6-deficient
of B chain±specific CD41 regulatory cells observed inT cells and APCs, there was no decrease in anti-LCMV
our model is unprecedented, indicating that there is acytotoxicity, which correlated with the inability of oral
limiting factor for induction of regulatory cells by oralinsulin to provide protection of stat6-deficient RIP-
antigens that are activating these lymphocytes in the
LCMV mice in vivo (Figure 3). Importantly, the differential
gut. This could be due to insufficiency of local antigen
effect of IL-4 on stat6-deficient cultures allowed us to presentation in the gut, or, alternatively and more likely,
test whether IL-4 predominantly acted on APCs or T to limited numbers (availability) of these regulatory cells
cells themselves. When stat6-deficient effector T cells among the peripheral autoreactive T cell repertoire. This
were cultured in the presence of wild-type APCs, the conclusion has important potential consequences for
suppressive effect of IL-4 was completely restored. A the treatment of human autoimmune diabetes. It means
similar but lesser effect was observed, when superna- that increasing the numbers of regulatory lymphocytes
tant from regulatory lymphocyte cultures was directly in vitro and transferring them back could be an effective
added to secondary LCMV T cell cultures (data not ªsecond-generationº immunotherapeutic approach. Im-
shown). Thus, IL-4 acts via the stat6-signaling pathway munodominance of the insulin B chain was first reported
in APCs resulting in the lack of expansion of LCMV- for diabetes prevention studies using subcutaneous
specific CD41 and CD81 T cell effectors. The precise insulin administration (Muir et al., 1995; Daniel and
changes induced in APCs are not yet known and are Wegmann, 1996). While tolerance induction after paren-
the subject of current studies. The in vivo relevance of teral insulin administration is likely to have a mechanism
this finding for diabetes pathogenesis is shown by the different from mucosal tolerance induction, oral B chain
selective suppression of autoreactive (anti-LCMV-NP) has also been associated with a shift from TH1 to TH2
CD81 responses that we documented in the pancreatic cytokines (Maron et al., 1998) and diabetes protection
in the NOD cotransfer model (Polanski et al., 1997).draining node of protected mice (Figure 4B).
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Since TGFb production did not strictly correlate with of IL-4 on T cell effector function in the presence of stat6-
protection (data not shown), although it might still be a competent compared to stat6-deficient APCs allows the
necessary immunosuppressive factor downstream or conclusion that a significant portion of the suppressive
upstream of IL-4 function, we further investigated the effect of IL-4 can be mediated by stat6-competent
role of IL-4 in bystander suppression. IL-4 is produced APCs.
by many regulatory cells and has also been shown to The following scenario emerges for the employment
exhibit a synergistic effect when given orally in conjunc- of bystander suppression to treat diabetes as well as
tion with low-dose oral antigen treatment (Inobe et al., possibly other autoimmune diseases. Regulatory cells
1998). Furthermore, IL-4 is also a differentiation factor primed against a target organ-specific autoantigen via
for TGFb secreting TH3 cells (Inobe et al., 1998). Although exposure to this antigen on mucosal surfaces, or poten-
impaired mucosal immune responses were reported in tially by other routes (Coon et al., 1999) traffic through
IL-4-deficient mice (Vajdy et al., 1995), oral tolerance the body and will reach the draining node of the diseased
induction was successful with a high-dose regimen organ. Self-antigens (such as insulin) released by an
(Garside, 1995), suggesting that IL-4-independent dele- ongoing autoimmune process are cross-presented by
tion/anergy of autoreactive T cells rather than the gener- resident APCs selectively in this lymphocyte compart-
ation of IL-4-deficient regulatory cells was the mecha- ment and lead to further activation of the regulatory T
nism for protection. In our RIP-NP model, diabetes cells. Resulting IL-4 secretion by the regulatory T cells
induction was not affected by the absence of IL-4, but in turn modifies APC activity leading to local silencing
IL-4-deficient RIP-NP mice were refractory to regulatory of autoaggressive lymphocytes specific for the disease-
T cell induction with oral insulin. To further corroborate initiating autoantigen presumably cross-presented on
these findings, protection studies were also conducted the same APC. Thus, such regulatory cells are only effi-
with stat6-deficient RIP-NP mice. The signal transducer cient if they are activated and present during organ
and activator of transcription 6 is required for mediating destruction. In conclusion, the induction of regulatory
responses to IL-4 and development of TH2 cells (Kaplan cells is of particular interest, since it may overcome
et al., 1996) but likely not for their survival (Vella et al., two fundamental problems that have hampered antigen-
1997). Similarly to the IL-4-deficient mice, STAT6-defi- specific immune interventions that directly target auto-
cient RIP-NP mice mounted an effective CTL response reactive destructive lymphocytes. First, the specificity
(Figure 4A) (Ihle et al., 1998) to eliminate the virus and of initiating destructive, autoreactive cells is not known
developed type 1 diabetes with comparable kinetics in most T cell±mediated autoimmune diseases, and sec-
(Figure 3). Again, as in IL-4-deficient mice, protection ond, epitope spreading may lead to a broadening of T
from type 1 diabetes by oral insulin administration was cell autoreactivity in the target organ. Knowledge of all
not achieved (Figure 3). These findings are in good self-antigens involved in an autoimmune process is not
agreement with previous studies by Nora Sarvetnick and required for induction of regulatory cells, which have
her colleagues (Gallichan et al., 1999) showing islet- to be directed to only one tissue-specific autoantigen
reactive TH2 regulatory cells in NOD mice over-express- involved in an ongoing autoimmune process.
ing IL-4 in their pancreatic islets. However, their experi-
ments did not provide any information about antigen
Experimental Procedures
specificity or the mechanism of action of such lympho-
cytes. Mice Breeding Scheme and Origin
The PDLN has recently been shown to be a critical Generation of H-2d RIP-LCMV-NP transgenic mice has been de-
checkpoint in the development of diabetes (Kurts et al., scribed previously (von Herrath et al., 1994). These mice were
crossed to the H-2d (BALB/c) background for 10 generations and1997). Our observations of regulatory T cell proliferation
express the nucleoprotein of LCMV in the pancreatic b cells and(Figure 4C) and suppression of diabetogenic T cell activ-
thymus but not in any other organs. Such mice were intercrossedity (Figure 4B) in the PDLN suggest that it also serves
with stat6-deficient (Kaplan et al., 1996) or IL-4-deficient (Jackson
as a checkpoint for immune regulation. Such targeted Laboratories) H-2d (BALB/c) mice, and the resulting stat6 or IL-4
immune regulation could circumvent problems associ- heterozygous NP-expressing or nonexpressing offspring were inter-
ated with systemic suppression of immune responses crossed for one generation. Offspring (F2) were used in all experi-
ments and were stat61/1, stat61/2, or stat62/2 or IL-41/1, IL-41/2, orand is thus likely to have fewer undesirable effects. The
IL-42/2 and did or did not express LCMV-NP yielding six experimen-differential specificity of regulatory and diabetogenic T
tal groups each.cells allows in principle for immune regulation of de-
structive, autoreactive T cell activity without a precise
Mouse Phenotypingknowledge of their specificity. The ªtertium daturº in this
The presence of the RIP-NP constructs was determined by slot-scenario are likely APCs, which were shown to suppress
blot hybridization or PCR using gene-specific probes or primer sets,
or support virus-specific T cell activity in the presence respectively, as described (Oldstone et al., 1991; von Herrath et al.,
of IL-4 or IL-12, respectively (Table 2). While the precise 1994a, 1994b). Stat6 animals were genotyped either by Southern
changes in APC function are currently not understood, blotting as described (Kaplan et al., 1996) or by PCR. Two indepen-
our findings suggest a powerful role for the stat6 signal- dent standard PCR reactions were performed to test for presence
of stat6 or stat6 gene copies disrupted by neomycin (neo) geneing pathway: while IL-4 did not inhibit the lytic function
integration. The stat6 wild-type gene was detected by primer com-of already differentiated effector virus-specific effector
bination stat6-sense (59-GGCCGAGGCTTCACATTTTGGC-39) andT cells, T cell expansion and IFNg production were sig-
STAT6-antisense (59-CCCGGATGACGTGTGCAATGG-39). A second
nificantly decreased (Table 2). This occurred in the pres- reaction determined the presence of the neo gene using the primer
ence of levels of externally added IL-4 that were not pair neo-sense and neo-antisense (59-CCGGCCACAGTCGATGA
higher than those found in supernatants of regulatory ATCC-39). Similarly, PCR reactions were performed for IL-4. The
reaction determined the presence of the IL-4 (59-GTGAGCAGATGAlymphocyte cultures. Importantly, the differential effect
Immunity
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CATGGGC39 and 59-CTTCAAGCATGGAGTTTTCCC-39) or neo genes CD11b (M1/70), CD11c (HL3), CD40 (HM40-3), CD44 (IM7), Il-2 (JES6-
1A12, JES6-5H4, and S4B6), IL-4 (11B11, BVD6-24G2, and BVD4-(59-CTTGGGTGGAGAGGCTATTC-39 and 59-AGGTGAGATGACAG
GAGATC-39). 1D11), IL-6 (MP5-20F3 and MP%-32C11), IL-10 (JES5-16E3 and
SXC-1), IFNg (R4-6A2 and XMG1.2), and TNFa (MP6-XT22).
Virus
Cytokine ELISAVirus used was LCMV strain Armstrong (ARM), clone 53b. LCMV was
Quantitation of cytokines in cell culture supernatants or after in vitroplaque purified three times on Vero cells and stocks prepared by a
stimulation was performed in a sandwich ELISA as described (Homannsingle passage on BHK-21 cells. Mice were infected with a single
et al., 1998). In brief, 96-well plates were precoated overnight at 48Cintraperitoneal dose of 105 pfu LCMV ARM.
with 2 mg/ml purified capture antibodies. After washing and blocking
with 10% FCS in PBS, serial dilution of supernatants and recombinantOral Antigens
cytokine standards (PharMingen) overnight at 48C. Washing and a 1Porcine insulin was provided by Novo Nordisk, Bagsvaerd, Denmark,
hr incubation with 1 mg/ml matched biotinylated detection were fol-and obtained as dry crystals from the very last stage of the purification
lowed by a 30 min incubation with a streptavidin-peroxidase conjugateprocess, immediately before formulation into the injectable product
(1:1000) (Boehringer Mannheim). For color reaction, H2O2 activatedused for patients. Porcine, human, and murine (I1II) insulin B chains
ABTS (2,2'-Azino-di-[3-ethylbenzthiazolin-6-sulfonic acid], Sigma) so-were also obtained from Novo Nordisk. Insulin and B chains were
lution in 0.1 M citric acid (pH 4.35) was added. Plates were read atsolubilized in acid buffer, pH adjusted, and the solution stored at 2208C
405 nm with an EL-800 microplate reader (Biotek) using DeltaSoft 3until used. Oral antigen was administered via a blunt-ended curved
(BioMetallics) software. For TGFb quantitation, the TGFb1 Emax Immu-feeding tube inserted into the esophagus/stomach. RIP-NP mice were
noAssay kit (Promega) was used.fed biweekly with 0.5 ml of an aqueous solution containing 1 mg
porcine insulin. Feeding was started 1 week prior to infection with
Flow CytometryLCMV and discontinued 9 weeks later. Control groups received 1 mg
Staining of cell surface antigen and intracellular antigens was per-of bovine serum albumin (BSA) at same intervals.
formed as described (Homann et al., 1998). For staining of intracellular
cytokines, cells were stimulated for 5±10 hr by either of the following
Generation and Expansion of Insulin B Chain±Specific
methods. Polyclonal stimulation was provided by 5 ng/ml PMA and
Regulatory Cells
500 ng/ml ionomycin (Sigma) or, alternatively, plate-bound anti-CD3
Single cell suspensions of spleen, pancreas draining, and mesenteric
and soluble anti-CD28 (Homann et al., 1998). Virus-specific stimulation
lymph nodes from protected and diabetic RIP-NP mice fed porcine
was provided by addition of 1026 M LCMV-NP118-126 peptide in theinsulin as well as nonfed mice were prepared by disrupting and press-
presence of 50 U/ml recombinant human IL-2. All stimulation cultures
ing organs through a steel mesh. CD41 T cells from pancreata were
contained 1 mg/ml Brefeldin A (BFA, #B7651, Sigma) to block protein
obtained by fractionated digestion with collagenase P (Boehringer
transport into post-Golgi compartments and allow cytokines to accu-
Mannheim) and separation with anti-CD4 coated magnetic beads (Dy-
mulate within cells. In some experiments, antigen-specific stimulation
nal). Cells were cultured in FCS-rich medium on irradiated (2000 rads)
was provided by LCMV-infected, irradiated PECs, and BFA was added
BALB/c peritoneal exudate cells (PEC) pulsed with 30 mg/ml porcine
for 5±10 hr after transfer to fresh PECs. Negative controls were stained
insulin B chain or B chain peptides. For some cultures, recombinant
with cytokine-specific PE-conjugated antibodies preincubated for 30
murine IL-4 was added at 40 ng/ml. After 1 week, cells were transferred
min at 48C with an excess of recombinant cytokine. Cells were acquired
to fresh PEC-coated plates and resuspended in FCS-rich medium
and analyzed on a FACSort or FACScalibur flow cytometer (Beckton
containing 5% ConA stimulated rat spleen supernatant containing ªT
Dickinson) using Cell Quest software (Beckton Dickinson).
cell growth factorº (TCGF) and B chain as well as irradiated syngeneic
spleen feeder cells. Stimulation with porcine B chain or peptides was
Immunohistochemistrygradually lowered to 2 mg/ml, IL-4 to 8 ng/ml, and cells were expanded
Tissues taken for histologic analysis were placed in Bouin's fixativeusing TCGF medium and feeder cells. After z2 months, IL-4 was
and then stained with hematoxylin and eosin. Immunochemical studieswithdrawn from some cultures, and cells were tested in vitro and in
were carried out on 6±10 mm cryomicrotome sections as describedvivo z6 weeks later. Under these culture conditions, only cells from
(von Herrath et al., 1994a).pancreas draining lymph nodes of protected mice could be maintained
and expanded for extended time periods. In some cases, these cells
CFSE Labeling for Cell Trackingwere then recultured in the presence of 8 ng/ml IL-4.
Regulatory cell cultures from spleens of protected or diabetic RIP-NPStimulation cultures for LCMV-specific lymphocytes. Splenocytes
mice were labeled with carboxy fluorescein succiminidylester (CFSE,obtained from LCMV-infected stat6-competent or -deficient mice 45
Molecular Probes) prior to i.v. transfer into prediabetic RIP-NP miceto 60 days post infection were stimulated in vitro for 6 days in the
(5 days post LCMV). Use of CFSE has been described (Homann et al.,presence of LCMV-infected, irradiated PECs or coated with LCMV
1998).NP H-2d (RPQASGVYM) peptide (1025 M final concentration). In some
experiments, IL-4 (8 ng/ml) or IL-12 (4 ng/ml) was added to stimulation
cultures. IFNg and IL-4 in culture supernatants were quantitated by Acknowledgments
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